Tumor Cells in a Hurry: Duct Tape will do!

A New Paper by Kickuchi, Keller and Colleagues on a completely new way of thinking about what Pax3:Foxo1a does. The paper is titled: Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma. In alveolar rhabdomyosarcoma, 70-75% of tumors carry the Pax3:Foxo1a oncogene. This oncogene seems to account for a large difference…
Continue Reading »

Recent Papers on Rhabdomyosarcoma – 16 January 2014

From Google Scholar Alerts Please note that some are abstracts requiring subscriptions or purchase of the full article, others provide a more comprehensive view of the paper. Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling S Park, J Lee, IG Do, J Jang, K Rho, S Ahn, L Maruja… - Scientific Reports,…
Continue Reading »

Recent Papers on Rhabdomyosarcoma – 14 January 2014

From Google Scholar Alerts Please note that some are abstracts requiring subscriptions or purchase of the full article, others provide a more comprehensive view of the paper. Phosphocaveolin-1 Enforces Tumor Growth and Chemoresistance in Rhabdomyosarcoma F Faggi, S Mitola, G Sorci, F Riuzzi, R Donato… - PLOS ONE, 2014 Abstract Caveolin-1 (Cav-1) can ambiguously behave…
Continue Reading »

Recent Papers on Rhabdomyosarcoma – 12 January 2014

Please note that some are abstracts requiring subscriptions or purchase of the full article, others provide a more comprehensive view of the paper. An approach to pleomorphic sarcomas: can we subclassify, and does it matter&quest JR Goldblum - Modern Pathology, 2014 ... Pleomorphic rhabdomyosarcoma is recognized by the presence of large cells with eosinophilic cytoplasm…
Continue Reading »

What Promising Drugs are on the Horizon?

20131225- Cynthia asked a valid question in response to a prior blog post: what new treatments look most promising for relapsed metastatic alveolar rhabdomyosarcoma? The most relevant answer is that the human relapsed rhabdomyosarcoma study ARST-0921 (bevacizumab vs temsirolimus) may have early results worth discussing with one's physician. The second most relevant answer is that…
Continue Reading »

We Want to Answer Your Questions About Rhabdo…

This is Charles (researcher). Lenny Wexler and I are in the midst of creating the scientific advisory board that complements the wider scientific advisory council. that said, we are happy to post short blogs about the topics of interest to you (with select links to more in-depth references). Quick ground rules: general topics are welcome,…
Continue Reading »

FDA Public Workshops on Rare Childhood Diseases

Jennifer Inman-Cartwright emailed me today saying that she sat in on a conference call with the Children's Cancer Caucus - Advocacy (CCCA) where the topic was the FDA and orphan drug issues. She forward the slide presentations which you can view and download. The first presentation was by James E. Valentine, MHS, JD Candidate at…
Continue Reading »

Early Life Factors and Risk of Childhood Rhabdomyosarcoma

By: Anshu Shrestha, Beate Ritz, Simona Ognjanovic, Christina A. Lombardi, Michelle Wilhelm and Julia E. Heck Frontiers in Public Health, 31 May 2013 - Although little is known about etiology of childhood rhabdomyosarcoma (RMS), early life factors are suspected in the etiology. We explored this hypothesis using linked data from the California Cancer Registry and…
Continue Reading »
Skip to toolbar